Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells

Mi Yeon Kang; Tae Jung Oh; Young Min Cho

doi:10.3803/EnM.2015.30.2.216

Articles

Page Path: HOME > Endocrinol Metab > Volume 30(2); 2015 > Article

Brief Report Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells: Mi Yeon Kang^*, Tae Jung Oh, Young Min Cho; Endocrinology and Metabolism 2015;30(2):216-220.
DOI: https://doi.org/10.3803/EnM.2015.30.2.216
Published online: June 30, 2015

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Corresponding author: Young Min Cho. Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea. Tel: +82-2-2072-1965, Fax: +82-2-762-9662, ymchomd@snu.ac.kr

*Current affiliation: Department of Internal Medicine, St. Carollo Hospital, 221 Sunkwang-ro, Suncheon, Korea.

• Received: July 14, 2014 • Revised: August 27, 2014 • Accepted: August 29, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

3,996 Views
44 Download
41 Web of Science
40 Crossref
44 Scopus

Full Article

Download PDF

ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
ACKNOWLEDGMENTS
Article information
References

ABSTRACT

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that increases glucose-stimulated insulin secretion in pancreatic β-cells. Since mitochondrial function is crucial to insulin secretion, we hypothesized that GLP-1 may increase mitochondrial biogenesis in pancreatic β-cells. We treated INS-1 rat insulinoma cells with GLP-1 or exendin-4 for 48 hours and measured mitochondrial mass and function. Both GLP-1 and exendin-4 increased mitochondrial mass by approximately 20%. The mitochondria/cytosol ratio was increased from 7.60±3.12% to 10.53±2.70% by exendin-4. In addition, GLP-1 increased the mitochondrial membrane potential and oxygen consumption. Proliferator-activated receptor-gamma coactivator 1α expression was increased approximately 2-fold by GLP-1 treatment. In conclusion, the present study presents evidence for a new mechanism of action by which GLP-1 improves pancreatic β-cell function via enhanced mitochondrial mass and performance.
Keywords: Glucagon-like peptide-1; Mitochondria; Diabetes mellitus; Beta cell; Insulin

INTRODUCTION

Mitochondrial dysfunction causes both insulin resistance and β-cell dysfunction, leading to glucose intolerance and diabetes [1 2]. In skeletal muscle, decreased mitochondrial fatty acid oxidation results in increased amounts of cytosolic long-chain acyl CoA and diacylglycerol, which leads to increased serine phosphorylation of insulin receptor substrate-1, thereby eliciting insulin resistance [3]. In pancreatic β-cells, decreased ATP generation due to impaired mitochondrial oxidative phosphorylation is linked to impaired insulin secretion, via a mechanism that reduces closure of the ATP-sensitive potassium channel [4]. In this regard, measures to improve mitochondrial function, either in the skeletal muscle or in the pancreatic β-cell, should be effective for treating diabetes.

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin secretion and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake [5 6]. Because of its efficacy in lowering blood glucose by stimulating β-cell insulin secretion, GLP-1 analogues and incretin enhancers (i.e., dipeptidyl peptidase-4 inhibitors) are widely used in the clinic to treat diabetes [7]. Interestingly, it was reported that GLP-1 stimulates ATP synthesis in pancreatic MIN6 β-cells [8], suggesting a new mechanism for improving β-cell function using GLP-1 therapy. In this study, we examined the effect of GLP-1 and its analogue on mitochondrial biogenesis in pancreatic β-cells.

INS-1 cell culture and glucose-stimulated insulin secretion: INS-1 rat insulinoma cells (passages 28 to 34) were grown in monolayer culture in RPMI-1640 supplemented with 10% fetal bovine serum, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 µM β-mercaptoethanol, 100 U/mL penicillin, and 100 µg/mL streptomycin, at 37℃ in a humidified atmosphere of 5% CO₂ and 95% air. For glucose-stimulated insulin secretion, INS-1 cells were seeded in 24-well plates and treated with 0, 100, or 200 nM GLP-1 (Sigma-Aldrich, St. Louis, MO, USA) for 48 hours. Cells were then washed twice with Kreb's ringer bicarbonate buffer (KRBB), incubated in KRBB at 37℃ for 1 hour, and exposed to 5 or 10 mM glucose for 1 hour. The culture supernatant was collected and stored at -20℃ until assayed for insulin concentration using enzyme-linked immunosorbent assay (ELISA, Linco Research, St. Charles, MO, USA).
Measurement of mitochondrial mass and membrane potential: INS-1 cells (1×10⁵) were seeded in six-well plates and incubated with GLP-1 (100 to 400 nM) or exendin-4 (100 to 200 nM, Sigma-Aldrich) for 48 hours. Mitochondrial mass was measured by 10-n-nonyl-acridine orange staining (NAO, Invitrogen, Carlsbad, CA, USA), and the mitochondrial membrane potential was measured using tetramethylrhodamine ethyl ester perchlorate (TMRE, Invitrogen) with a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), following the manufacturers' protocols. The strength of NAO or TMRE staining was expressed as the mean fluorescence intensity (MFI).
Transmission electron microscopy: INS-1 cells (5×10⁵) were seeded in 60-mm plates and incubated with exendin-4 for 48 hours. Cells were collected and processed for electron microscopy using standard methods. Ten random pictures were taken at a magnification of ×5,000, using an H-7100 transmission electron microscope (Hitachi, Tokyo, Japan). The volume density of mitochondria was estimated using a point-counting method in a blinded fashion by two separate examiners. For each set of 10 pictures, the average volume density was calculated, and the mean of 10 values was used to estimate the volume density for each individual cell.
Measurement of oxygen consumption: Oxygen consumption was measured using a high-resolution respirometer (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria) according to the manufacturer's instructions. A suspension of INS-1 cells at 1×10⁶ cells/mL in a 2-mL volume of culture medium (RPMI-1640) was measured in the respirometer at 37℃.
Reverse transcriptase polymerase chain reaction: Total RNA from cells was prepared using an RNeasy Mini kit (Qiagen, Valencia, CA, USA). cDNA was obtained from 1 µg RNA using random hexamers and avian myeloblastosis virus reverse transcriptase (Invitrogen). Samples were amplified in a Gene Amp polymerase chain reaction (PCR) system 9600 (Perkin-Elmer/Cetus, Norwalk, CT, USA). Digital images of the PCR products separated on 1% agarose gels were analyzed using a Gel Doc 2000 (BioRad Inc., Richmond, CA, USA).
Statistical analysis: Data are presented as means±SD. Nonparametric methods, including Kruskal-Wallis tests, Wilcoxon signed-rank tests, and Mann-Whitney tests, were used to evaluate statistical significance. Values for P<0.05 were considered significant.

Effects of GLP-1 and its analogue on insulin secretion and mitochondrial biogenesis in INS-1 cells: GLP-1 treatment of INS-1 cells for 48 hours enhanced glucose-stimulated insulin secretion (Fig. 1A) and mitochondrial mass (Fig. 1B, C). GLP-1 at 100, 200, and 400 nM increased NAO staining intensity to 121.64±11.54, 127.48±15.47, and 126.94±12.89 MFI, respectively (n=10) (Fig. 1C). A similar result was obtained using another mitochondrial dye (MitoTracker Green, data not shown). When mitochondrial density was measured using a point-counting method on transmission electron microscopy images, the mitochondria/cytosol area ratio was significantly increased by 100 nM exendin-4, from 7.60±3.12% to 10.53±2.70% (Fig. 1D, E). The expression of proliferator-activated receptor-gamma coactivator 1 α (PGC1α), a key regulator of mitochondrial biogenesis, was increased dramatically after 1 hour of GLP-1 treatment; after 4 hours, expression decreased gradually but remained above control levels for up to 48 hours of treatment (Fig. 1F).
Effects of GLP-1 and exendin-4 on mitochondrial function in INS-1 cells: The intensity of TMRE staining, which is an indicator of the strength of the mitochondrial membrane potential, was increased in INS-1 cells treated with GLP-1 or exendin-4 for 48 hours (Fig. 2A). In line with this finding, the oxygen consumption rate of cells treated with GLP-1 for 48 hours exhibited a significant increase relative to controls (56.3±2.8 µmol/sec/10⁵ cells vs. 42.0±1.6 µmol/sec/10⁵ cells, P<0.05) (Fig. 2B).

DISCUSSION

Because mitochondrial oxidative phosphorylation is crucial to glucose-stimulated insulin secretion [4], the mechanisms mediating the effects of GLP-1 on mitochondria in pancreatic β-cells deserve further study. One possible mechanism is the mobilization of calcium into the mitochondrial matrix after GLP-1 treatment, which has been reported to enhance mitochondrial function in pancreatic MIN6 β-cells, possibly through the activation of several Krebs cycle dehydrogenases [8] and also in vascular smooth muscle cells [9]. Interestingly, in hepatocytes, nonapeptide fragments of GLP-1 (i.e., GLP-1 [28-36] amide) were shown to enter the cytoplasm rapidly and target mitochondria in a GLP-1 receptor-independent manner, and to be associated with decreased gluconeogenesis and oxidative stress [10]. However, in the present study, exendin-4 also exhibited a stimulatory effect on mitochondrial mass and function. Therefore, signaling through the GLP-1 receptor appears to be sufficient to increase both mitochondrial mass and function in pancreatic β-cells.

We report here a novel effect of GLP-1 on mitochondrial biogenesis and function. In INS-1 cells, GLP-1 and exendin-4 treatment triggered an increase in mitochondrial mass, mitochondrial density, mitochondrial membrane potential, and oxygen consumption. These increases were accompanied by up-regulation of PGC1α, a key regulator of mitochondrial biogenesis [11]. However, further studies are needed to characterize the time-course of GLP-1-stimulated biogenesis, as it relates to that of PGC1α expression. In conclusion, the present study provides evidence for a new mechanism of action of GLP-1 in pancreatic β-cells, linking mitochondrial biogenesis and function to glucose-stimulated insulin secretion.

Acknowledgements

ACKNOWLEDGMENTS

We thank Dr. Hyung Jin Choi for the helpful discussions and Ms. So Hee Kim for her technical assistance. This study was supported in part by the Seoul National University Hospital Research Fund and by a KES Research Grant Award.

Article information

CONFLICTS OF INTEREST: Y.M.C. has received lecture or consultation fees from MSD, Lilly, Novartis, Astra-Zeneca, and Boehringer-Ingelheim.

References

1. Cho YM, Park KS, Lee HK. Genetic factors related to mitochondrial function and risk of diabetes mellitus. Diabetes Res Clin Pract 2007;77(Suppl 1):S172–S177. Article PubMed
2. Kwak SH, Park KS, Lee KU, Lee HK. Mitochondrial metabolism and diabetes. J Diabetes Investig 2010;1:161–169.Article PubMed PMC
3. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384–387. Article PubMed
4. Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic beta-cells. Nature 2001;414:807–812. Article PubMed PDF
5. Cho YM, Fujita Y, Kieffer TJ. Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physiol 2014;76:535–559. Article PubMed
6. Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther 2012;135:247–278. Article PubMed
7. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2013;28:262–274. Article PubMed PMC
8. Tsuboi T, da Silva Xavier G, Holz GG, Jouaville LS, Thomas AP, Rutter GA. Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem J 2003;369(Pt 2):287–299. Article PubMed PMC PDF
9. Morales PE, Torres G, Sotomayor-Flores C, Pena-Oyarzun D, Rivera-Mejias P, Paredes F, Chiong M. GLP-1 promotes mitochondrial metabolism in vascular smooth muscle cells by enhancing endoplasmic reticulum-mitochondria coupling. Biochem Biophys Res Commun 2014;446:410–416. Article PubMed
10. Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011;167:177–184. Article PubMed
11. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78–90. Article PubMed PDF

Fig. 1

Effects of glucagon-like peptide-1 (GLP-1) or exendin-4 on insulin secretion (A, n=6), mitochondrial mass (C, n=10), mitochondrial density (E, n=10), and proliferator-activated receptor-gamma coactivator 1 α (PGC1α) expression (F) in INS-1 cells. (B) A representative fluorescence activated cell sorting analysis for 10-n-nonyl-acridine orange staining (NAO) intensity, as summarized in (C). (D) Representative transmission electron microscopy images used to estimate the mitochondria/cytosol area ratios shown in concentration (conc). MFI, mean fluorescence intensity; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. ^aP<0.05; ^bP<0.01 compared with the control.

Fig. 2

Glucagon-like peptide-1 (GLP-1) increases mitochondria membrane potential (A, n=6) and cellular oxygen consumption rate (B, n=4). TMRE, tetramethylrhodamine ethyl ester perchlorate; MFI, mean fluorescence intensity. ^aP<0.05; ^bP<0.01 compared with control.

Figure & Data

References

Citations

Citations to this article as recorded by

New fraternine analogues: Evaluation of the antiparkinsonian effect in the model of Parkinson's disease
Andréia Biolchi Mayer, Henrique de Oliveira Amaral, Danilo Gustavo R. de Oliveira, Gabriel Avohay Alves Campos, Priscilla Galante Ribeiro, Solange Cristina Rego Fernandes, Adolfo Carlos Barros de Souza, Raffael Júnio Araújo de Castro, Anamélia Lorenzetti
Neuropeptides.2024; 103: 102390. CrossRef
Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
Lidan Hu, Wenmin Wang, Xiangjun Chen, Guannan Bai, Liangjian Ma, Xin Yang, Qiang Shu, Xuekun Li
Brain‐X.2024;[Epub] CrossRef
Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice
Vicki Wang, Kuan-Yin Tseng, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Lun Lan, Zi-Rong Chen, Kuo-Hsing Ma, Nigel H. Greig, Jin Jung, Ho-II Choi, Lars Olson, Barry J. Hoffer, Yuan-Hao Chen
Journal of Biomedical Science.2024;[Epub] CrossRef
Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro
Maija Vaittinen, Mariana Ilha, Elena Herbers, Anita Wagner, Kirsi A. Virtanen, Kirsi H. Pietiläinen, Eija Pirinen, Jussi Pihlajamäki
Diabetes Research and Clinical Practice.2023; 199: 110635. CrossRef
The cardioprotective effect of human glucagon‐like peptide‐1 receptor agonist (semaglutide) on cisplatin‐induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways
Marwa Mohamed Atef, Yasser Mostafa Hafez, Omnia Safwat El‐Deeb, Eman H. Basha, Radwa Ismail, Hanan Alshenawy, Rasha Osama El‐Esawy, Amira Kamel Eltokhy
Cell Biochemistry and Function.2023; 41(4): 450. CrossRef
Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
Yutong Zhou, Wendong Suo, Xinai Zhang, Jiaojiao Liang, Weizhe Zhao, Yue Wang, Hong Li, Qing Ni
Biomedicine & Pharmacotherapy.2023; 168: 115669. CrossRef
Soft X-ray tomography to map and quantify organelle interactions at the mesoscale
Valentina Loconte, Jitin Singla, Angdi Li, Jian-Hua Chen, Axel Ekman, Gerry McDermott, Andrej Sali, Mark Le Gros, Kate L. White, Carolyn A. Larabell
Structure.2022; 30(4): 510. CrossRef
Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
Belma Turan, Aysegul Durak, Yusuf Olgar, Erkan Tuncay
Molecular and Cellular Biochemistry.2022; 477(11): 2609. CrossRef
Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs
Carolin Thomas, Lia Wurzer, Ernst Malle, Michael Ristow, Corina T. Madreiter-Sokolowski
Frontiers in Aging.2022;[Epub] CrossRef
Anti-cancer effects of sitagliptin, vildagliptin, and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation
POOJA JAISWAL, VERSHA TRIPATHI, ANSHUL ASSAIYA, DHARMENDRA KASHYAP, RAHUL DUBEY, ANAMIKA SINGH, JANESH KUMAR, HEM CHANDRA JHA, RAJESH SHARMA, AMIT KUMAR DIXIT, HAMENDRA SINGH PARMAR
BIOCELL.2022; 46(12): 2645. CrossRef
Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats
Ilijana Babic, Dominic Sellers, Paul L Else, Jessica Nealon, Ashleigh L Osborne, Nagesh Pai, Katrina Weston-Green
Journal of Psychopharmacology.2021; 35(3): 284. CrossRef
Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease
Vicki Wang, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Yu-Ching Chou, Zhao-Yang Fu, Li-Wen Lai, Jin Jung, Hoi-II Choi, Doo-Sup Choi, Yazhou Li, Lars Olson, Nigel H. Greig, Barry J. Hoffer, Yuan-Hao Chen
ACS Pharmacology & Translational Science.2021; 4(2): 858. CrossRef
Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms
Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar, Marina Sokovi
Oxidative Medicine and Cellular Longevity.2021; 2021: 1. CrossRef
Vernicia fordii (Hemsl.) Airy Shaw extract stimulates insulin secretion in pancreatic β-cells and improves insulin sensitivity in diabetic mice
Jimin Hyun, Mi Hyeon Park, Yo Han Lee, Youngeun Lee, Su Ji Jeong, Sun Sil Choi, Keon Woo Khim, Hye Jin Eom, Jin-Hoe Hur, Chan Young Park, Jae-Ick Kim, Jiyoung Park, Hyung Won Ryu, Hyun-Jun Jang, Sei-Ryang Oh, Jang Hyun Choi
Journal of Ethnopharmacology.2021; 278: 114238. CrossRef
Connecting the dots between mitochondrial dysfunction and Parkinson’s disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity
Ishnoor Kaur, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Lotfi Aleya, Simona Bungau
Environmental Science and Pollution Research.2021; 28(28): 37060. CrossRef
Neuromodulatory effects of anti-diabetes medications: A mechanistic review
Habib Yaribeygi, Milad Ashrafizadeh, Neil C. Henney, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar
Pharmacological Research.2020; 152: 104611. CrossRef
Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
Shu-Yi Wang, Shey-Lin Wu, Ta-Cheng Chen, Chieh-Sen Chuang
International Journal of Environmental Research and Public Health.2020; 17(13): 4805. CrossRef
Visualizing subcellular rearrangements in intact β cells using soft x-ray tomography
Kate L. White, Jitin Singla, Valentina Loconte, Jian-Hua Chen, Axel Ekman, Liping Sun, Xianjun Zhang, John Paul Francis, Angdi Li, Wen Lin, Kaylee Tseng, Gerry McDermott, Frank Alber, Andrej Sali, Carolyn Larabell, Raymond C. Stevens
Science Advances.2020;[Epub] CrossRef
Nutrient Sensor mTOR and OGT: Orchestrators of Organelle Homeostasis in Pancreatic β-Cells
Nicholas Esch, Seokwon Jo, Mackenzie Moore, Emilyn U. Alejandro, Yingke Xu
Journal of Diabetes Research.2020; 2020: 1. CrossRef
Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1
Ana D. Martins, Mariana P. Monteiro, Branca M. Silva, Alberto Barros, Mário Sousa, Rui A. Carvalho, Pedro F. Oliveira, Marco G. Alves
Toxicology and Applied Pharmacology.2019; 362: 1. CrossRef
Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions
Hiroshi Watanabe, Yuki Enoki, Toru Maruyama
Biological and Pharmaceutical Bulletin.2019; 42(9): 1437. CrossRef
Recent Advances in Drug Repurposing for Parkinson’s Disease
Xin Chen, Giuseppe Gumina, Kristopher G. Virga
Current Medicinal Chemistry.2019; 26(28): 5340. CrossRef
Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function
Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
Journal of Cellular Physiology.2019; 234(6): 8402. CrossRef
Liraglutide protects against glucolipotoxicity‐induced RIN‐m5F β‐cell apoptosis through restoration of PDX1 expression
Edy Kornelius, Hsin‐Hua Li, Chiung‐Huei Peng, Yi‐Sun Yang, Wei‐Jen Chen, Yan‐Zin Chang, Yi‐Chiao Bai, Stanley Liu, Chien‐Ning Huang, Chih‐Li Lin
Journal of Cellular and Molecular Medicine.2019; 23(1): 619. CrossRef
The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts
Subhashis Pal, Shailendra K. Maurya, Sourav Chattopadhyay, Shyamsundar Pal China, Konica Porwal, Chirag Kulkarni, Sabyasachi Sanyal, Rohit A. Sinha, Naibedya Chattopadhyay
Biochemical Pharmacology.2019; 164: 34. CrossRef
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
Holly Green, Panagiota Tsitsi, Ioanna Markaki, Dag Aarsland, Per Svenningsson
CNS Drugs.2019; 33(2): 143. CrossRef
Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
Enrico Bagnoli, Una FitzGerald
European Journal of Neuroscience.2019; 49(4): 422. CrossRef
Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis
Chengcong Chen, Ying Huang, Yongmei Zeng, Xiyan Lu, Guoqing Dong
BMC Cardiovascular Disorders.2019;[Epub] CrossRef
Acute exposure to 3‑deoxyglucosone at high glucose levels impairs insulin secretion from β‑cells by downregulating the sweet taste receptor signaling pathway
Xiudao Song, Guoqiang Liang, Min Shi, Liang Zhou, Fei Wang, Lurong Zhang, Fei Huang, Guorong Jiang
Molecular Medicine Reports.2019;[Epub] CrossRef
Translational approaches to restoring mitochondrial function in Parkinson's disease
Heather Mortiboys, Ruby Macdonald, Thomas Payne, Matilde Sassani, Thomas Jenkins, Oliver Bandmann
FEBS Letters.2018; 592(5): 776. CrossRef
Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy
Eridan Rocha-Ferreira, Laura Poupon, Aura Zelco, Anna-Lena Leverin, Syam Nair, Andrea Jonsdotter, Ylva Carlsson, Claire Thornton, Henrik Hagberg, Ahad A Rahim
Brain.2018; 141(10): 2925. CrossRef
Current perspective of mitochondrial biology in Parkinson's disease
Navneet Ammal Kaidery, Bobby Thomas
Neurochemistry International.2018; 117: 91. CrossRef
Humanin promotes mitochondrial biogenesis in pancreatic MIN6 β-cells
Qingqing Qin, Jieqiong Jin, Fang He, Yongqin Zheng, Tingting Li, Yun Zhang, Jundong He
Biochemical and Biophysical Research Communications.2018; 497(1): 292. CrossRef
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson, Yazhou Li, Iciar Aviles-Olmos, Thomas T Warner, Patricia Limousin, Andrew J Lees, Nigel H Grei
The Lancet.2017; 390(10103): 1664. CrossRef
Alogliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits
Xiaowei Zhang, Zhiwei Zhang, Yungang Zhao, Ning Jiang, Jiuchun Qiu, Yajuan Yang, Jian Li, Xue Liang, Xinghua Wang, Gary Tse, Guangping Li, Tong Liu
Journal of the American Heart Association.2017;[Epub] CrossRef
Potential therapeutic interventions for chronic kidney disease‐associated sarcopenia via indoxyl sulfate‐induced mitochondrial dysfunction
Yuki Enoki, Hiroshi Watanabe, Riho Arake, Rui Fujimura, Kana Ishiodori, Tadashi Imafuku, Kento Nishida, Ryusei Sugimoto, Saori Nagao, Shigeyuki Miyamura, Yu Ishima, Motoko Tanaka, Kazutaka Matsushita, Hirotaka Komaba, Masafumi Fukagawa, Masaki Otagiri, To
Journal of Cachexia, Sarcopenia and Muscle.2017; 8(5): 735. CrossRef
The pancreas: Bandmaster of glucose homeostasis
Nathalie Jouvet, Jennifer L. Estall
Experimental Cell Research.2017; 360(1): 19. CrossRef
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Dilan Athauda, Thomas Foltynie
Drug Discovery Today.2016; 21(5): 802. CrossRef
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus
Long Jin, Sun Woo Lim, Jian Jin, Byung Ha Chung, Chul Woo Yang
Translational Research.2016; 174: 122. CrossRef
Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases
Tae Jung, Kyung Choi
International Journal of Molecular Sciences.2016; 17(2): 192. CrossRef